Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $288.3 million.

  • Voyager Therapeutics' Liabilities and Shareholders Equity fell 3232.79% to $288.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 1939.45%. This contributed to the annual value of $393.0 million for FY2024, which is 1189.05% up from last year.
  • Latest data reveals that Voyager Therapeutics reported Liabilities and Shareholders Equity of $288.3 million as of Q3 2025, which was down 3232.79% from $322.1 million recorded in Q2 2025.
  • Voyager Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $469.6 million during Q1 2024, with a 5-year trough of $159.4 million in Q4 2022.
  • Over the past 5 years, Voyager Therapeutics' median Liabilities and Shareholders Equity value was $294.7 million (recorded in 2023), while the average stood at $292.9 million.
  • As far as peak fluctuations go, Voyager Therapeutics' Liabilities and Shareholders Equity soared by 12043.79% in 2023, and later tumbled by 3232.79% in 2025.
  • Over the past 5 years, Voyager Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $193.9 million in 2021, then dropped by 17.8% to $159.4 million in 2022, then surged by 120.44% to $351.3 million in 2023, then increased by 11.89% to $393.0 million in 2024, then fell by 26.65% to $288.3 million in 2025.
  • Its last three reported values are $288.3 million in Q3 2025, $322.1 million for Q2 2025, and $353.2 million during Q1 2025.